Drug Information

Drug General Information
Drug ID
D07GJZ
Former ID
DNC000479
Drug Name
CQA 206-291
Drug Type
Small molecular drug
Indication Parkinson's disease [ICD9: 332; ICD10:G20] Phase 3 [531697]
Structure
Download
2D MOL

3D MOL
Formula
C21H32N4O2S
Canonical SMILES
CCN1C=C2CC3C(CC(CN3C)NS(=O)(=O)N(CC)CC)C4=C2C1=CC=C4
InChI
1S/C21H32N4O2S/c1-5-24-13-15-11-20-18(17-9-8-10-19(24)21(15)17)12-16(14-23(20)4)22-28(26,27)25(6-2)7-3/h8-10,13,16,18,20,22H,5-7,11-12,14H2,1-4H3/t16-,18?,20+/m0/s1
InChIKey
ARTRTLXKTHJPRW-LYNLNPNLSA-N
CAS Number
CAS 453562-69-1
PubChem Compound ID
146782
PubChem Substance ID
46223963, 56459364, 79172471, 104414920, 127449900, 135102668, 233725606
ChEBI ID
ChEBI:51098
Target and Pathway
Target(s) D(2) dopamine receptor Target Info Agonist [537689]
KEGG Pathway Rap1 signaling pathway
cAMP signaling pathway
Neuroactive ligand-receptor interaction
Gap junction
Dopaminergic synapse
Parkinson's disease
Cocaine addiction
Alcoholism
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Dopamine receptor mediated signaling pathway
Nicotine pharmacodynamics pathway
Reactome Dopamine receptors
G alpha (i) signalling events
WikiPathways Hypothetical Network for Drug Addiction
Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
Genes and (Common) Pathways Underlying Drug Addiction
GPCR ligand binding
GPCR downstream signaling
Nicotine Activity on Dopaminergic Neurons
References
Ref 531697CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's disease. Clin Neuropharmacol. 1990 Aug;13(4):303-11.
Ref 537689The antiparkinsonian activity of CQA 206-291, a new D2 dopamine receptor agonist. Clin Neuropharmacol. 1989 Feb;12(1):55-9.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.